



Identification of *Candida* Species Isolated from Vulvovaginal Candidiasis Patients by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) in Yasuj Southwestern Iran

Maral Gharaghani¹, Bahram Ahmadi², Marzie Taheripour Sisakht³, Owrangle Ilami⁴, Shahintaj Aramesh⁵, Fariba Mouhamadi⁵, Zohreh Barati⁵, Shohreh Roozmeh⁶, Haniyeh Mohammadi³ and Sadegh Nouripour-Sisakht^{4,*}

¹Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

²Department of Microbiology and Parasitology, School of Para-Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

³Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

⁴Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

⁵Department of Obstetrics and Gynecology, Yasuj University of Medical Sciences, Yasuj, Iran

⁶Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding author: Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran. Tel: +98-7433230290, Email: nooripoor@razi.tums.ac.ir

Received 2017 December 20; Revised 2018 July 15; Accepted 2018 July 16.

Abstract

Background: Vulvovaginal candidiasis (VVC) is a frequent infection in females at the reproductive age. Furthermore, the most common causative agent is *Candida albicans* yet in the recent years, the incidence of non-*albicans* species has increased.

Objectives: The main aim of this study was the isolation and identification of various *Candida* species from patients with vulvovaginal candidiasis by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in Yasuj, Iran.

Methods: Three hundred and ten suspected women females vaginitis were sampled and examined. Genomic DNA was extracted from fresh colonies by phenol-chloroform glass bead methods. Polymerase chain reaction (PCR) amplification was performed based on the ribosomal DNA internal transcribed spacer (rDNA-ITS), and specific electrophoretic patterns of PCR products after digestion with *MspI* enzyme used for species identification.

Results: The cultures were positive for 160 (51.6%) vaginal samples. *Candida albicans* (86.8%) was the most common species among the isolates, followed by *C. glabrata* (3.77%) and *C. krusei* (3%). Multispecies with two *Candida* were identified in nine patients.

Conclusions: Vulvovaginal candidiasis is more prevalent among females in Yasuj and the predominant agent is *C. albicans*. In addition, correct identification of *Candida* species could play an important role in management and treatment of VVC.

Keywords: Vulvovaginal Candidiasis, Infection, *Candida albicans*

1. Background

Vulvovaginal candidiasis (VVC) is an usual infection among females, which occurs due to different species of *Candida* (1). *Candida* is the second most common cause of vaginal infection after bacterial vaginitis (2). Many reports have suggested that the majority of sexually active females will experience at least one symptomatic vaginal candidiasis during their life; 40% to 50% of these females will experience a second episode and 5% to 10% develop the recurrent form, characterized by three or more episodes in a year (2, 3). Predisposing factors for VVC may include pregnancy, antimicrobial therapy, uncontrolled diabetic mel-

litus, using of high-estrogen oral contraceptives and hormone drug replacement therapy, use of corticosteroids, cancer chemotherapy, organ transplantation, tight fitting closing, increase in sexual activity, and vaginal douching (4). Symptomatic VVC is characterized by vulvar pruritus, burning, sureness, abnormal vaginal discharge, irritation, and dyspareunia (5, 6). Differential diagnosis of vulvovaginal candidiasis from bacterial vaginitis and trichomoniasis is difficult based on signs and symptoms and leads to suboptimal care (7).

Vulvovaginal candidiasis is most commonly caused by *Candida albicans* yet in the recent years the rate of infec-

tion by non-*albicans* species, such as *C. glabrata*, has increased (5, 8). In addition, the correct identification and differentiation of etiological agents is very important for early treatment and preventing of invasion (9). For a long time, traditional microbiological procedures, such as morphology and biochemical methods, were used to identify *Candida* species, yet these methods are time-consuming, inaccurate to identify, and lacking the necessary validity (10-12). Several DNA-based methods have been developed to improve the identification of fungi species (10, 13). The ITS regions of rDNA contains highly variable nucleotide sequences that have been used for identification of *Candida* species in the PCR assay. The advantages of PCR-RFLP method for differentiation of *Candida* species in clinical samples is simple, easy-to-perform, cost-effective, and rapid (11).

2. Objectives

The objective of the current study was to identify and determine various species of *Candida* isolates from females with VVC, using PCR-RFLP for elucidation of epidemiological aspects of vulvovaginal candidiasis.

3. Methods

3.1. Ethics Statement

The ethics committee of the Yasuj University of Medical Sciences approved this study with ethical no.IR.YUMS.REC.1395.29.

3.2. Clinical Samples

This descriptive study was conducted over a period of one year (2016 to 2107) on vaginal samples of patients clinically suspected and diagnosed with VVC that had referred to gynecology and (obstetrics) private midwifery clinics (Yasuj, Iran). The inclusion criteria included living in Yasuj city, being in the menstrual phase, and having an active sexual life while females with pregnancy, and local or systemic treatment for vaginitis were excluded from the study. The samples were collected by sterile cotton swabs from the lateral wall of patients' vagina and cultured on Sabouraud dextrose agar (Merck, Germany) plates supplemented with 50 mg/L chloramphenicol to avoid bacterial growth and incubated at 35°C for two days. To ensure purity of the isolates, all yeasts were plated on CHROMagar *Candida* medium (CHROMagar™, Rambach™, AquaCHROM™).

3.3. Molecular Identification

For precise species identification, the extraction and purification of genomic DNA was done from colonies by using previously described methods by Mirhendi et al. (11). Briefly, a loop full of fresh colonies was added to in a 1.5-mL micro tube, containing 300 μ L of phenol-chloroform (1:1) solution, 300 μ L of lysis buffer (10 mM Tris, 1% SDS, 1 mM EDTA (pH 8), 100 mM NaCl, 2% Triton X-100), and equal to 300 μ L of glass beads (0.5 mm in diameter). The suspension was vortexed vigorously for five minutes, centrifuged at 10000 rpm for five minutes, and then the supernatant was transferred to a new tube and re-extracted once more with chloroform. The nucleic acid was precipitated with 2.5 mL volume of cold absolute ethanol and 0.1 mL volume of sodium acetate (pH 5.2) centrifuged at 10000 rpm for 10 minutes at 4°C and the pellets were washed with 300 mL of 70% ethanol, air dried, and finally the pellets rehydrated in 100 μ L TE buffer (10 mM Tris, 1 mM EDTA) and were stored at -20°C until use for PCR amplification.

3.4. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP)

The PCR-RFLP method was carried out according to an already available method, previously described by Mirhendi et al. (11). Briefly, 0.2 μ M of each forward ITS1 (5'-TCC GTAGGT GAA CCT GCG G-3') and reverse ITS4 (5'-TCC TCC GCT TAT TGA TAT GC-3') universal primers, 1 μ L of template DNA, 12.5 μ L of premix (Amplicon, Denmark), and enough deionized distilled water up to a final volume of a 25 μ L were used for PCR amplification of the ITS1-5.8S-ITS2 rDNA region by thermal conditions according to the following scheme: Initial denaturation during five minutes at 94°C, 35 cycles of amplification consisting of denaturation for 30 seconds at 94°C, annealing for 30 seconds at 58°C and extension for on minutes at 72°C, followed by final extension step at 72°C for seven minutes. To achieve precise strain discriminatory patterns, PCR products were digested in a final reaction volume of 15 μ L containing a 10 μ L of PCR product, 1U of restriction enzyme *MspI* (Fermentas, Vilnius, Lithuania), 1.5 μ L of relevant buffer, and 3 μ L of deionized distilled water at 37°C for two hours. Amplified and digested products were analyzed by agarose gel electrophoresis in TBE buffer (Tris 0.09 M, EDTA 2mM, Boric acid 0.09 M) containing 0.5 μ /mL of ethidium bromide, at 100 V for approximately one hour using 1.5% and 2% agarose gels, respectively. For species identification, the size of the digested fragment was compared with reference band profiles (13).

4. Results

Overall, 310 females suspected of vulvovaginal candidiasis were examined in the present study. The mean age




Figure 1. Agarose gel electrophoresis of restriction fragments length polymorphism ITS gene from *Candida* species isolated from vulvovaginal candidiasis with *Candida albicans* (lanes 1-4), *C. glabrata* (lanes 5-6), *C. krusei* (lanes 7-9), *C. kefyr* (lane 10), and Lane M represents a 100 bp size molecular marker.

of the patients was 31 with a range of 19 to 53 years. Itching, irritation, discharge, dyspareunia, and erythema were found in 80% of patient. In the present study, 160 (51.6%) patients of 310 suspected females were positive for vulvovaginal candidiasis. The culture results show that *C. albicans* was the predominant species 139/160 (86.8%), followed by *C. glabrata* 6/160 (3.77%), *C. krusei* 5/160 (3.1%), mixed infection of *C. albicans* and *C. glabrata* 7/160 (4.37%), *C. albicans* and *C. krusei* 2/160 (1.3%), and *C. kefyr* 1/160 (0.65%). The overall prevalence of none-*albicans* *Candida* species in the study was 13.2%. Vaginal samples 151/160 (94.35%) contained only one species of *Candida* and 9/160 (5.62%) more than one species of *Candida*. Non-*albicans* species were more commonly isolated from the culture of patients with mixed infection. Figure 1 shows the PCR-RFLP results for identification of isolated *Candida* species.

5. Discussion

Vulvovaginal candidiasis results from increasing growth of *Candida* species in the mucous of genital tract and has enlarged extremely in the recent years (14). The PCR-RFLP was used to identify yeast isolated from patients with VVC. The frequency of VVC varied from 5.4% to 84% in reports from Iran and abroad (3, 7, 9, 15, 16). The findings revealed that the prevalence of *Candida* vaginitis was 160 (51.6%). These results are similar to Mohamadi et al. (17), Hedayati et al. (15), and Rasti et al.'s studies (18). Furthermore, the present study indicated the high rate of VVC in 30- to 40-year-olds, which is in agreement with the study of Mohamadi et al. (17), while it is in contrast with Rezaei-Matekolaei et al. (19).

The current results showed the high prevalence of *C. albicans* in VVC. This finding was in concordance with the studies of Roshan et al. (86.2%) (9), Roubary et al. (82.2%) (16), Rezaei-Matekolaei et al. (88.2%) (19), Mahmoudi Rad (65.1%) (20), and Fan et al. (89.5%) (21). On the other hand, during the last decade, the frequency of non-*albicans* species has increased. The current study documented a prevalence of 13.9% for non-*albicans* species, while this is in contrast to other studies, for example Lakshmi (7) reported a striking increase of non-*albicans* *Candida* species with a prevalence of 59.2% from all *Candida* species. Also, Richter et al. (22) reported that 24% of 593 symptomatic patients were non-*albicans* species in 1998 to 2001. Hedayati et al., using CHROM *Candida* agar medium for identification of two major *Candida* species and Hicandida kit for final differentiation of *Candida* species, showed non-*albicans* isolates of *Candida*, such as *C. glabrata*, *C. dubliniensis*, *C. kefyr*, and *C. pintolopesii* were more frequent than *C. albicans* (57.5% versus 42.5%) (15). However, non-*albicans* *Candida* species may cause more severe symptoms and are often more difficult to treat (22, 23). The second most common isolated species in this study was *C. glabrata*, which was in agreement with similar studies (9, 16) yet Lakshmi and Budhani reported *C. tropicalis* as the common non-*albicans* species (7, 14, 24).

The prevalence of *C. glabrata* in this study was 7%, however, this is in contrast to other reported Abu-Elteen and Lakshmi by CHROMagar *Candida* and conventional mycological methods that reported 32.5% and 11.1% prevalence for *C. glabrata*, respectively (25). Also, Trama et al. reported a higher rate of *C. glabrata* species than the current study: 14.3% of 1316 isolates in vulvovaginitis (6). As well as, a report from India indicated that *C. glabrata* was major agent (50.4%) in VVC (25). The third *Candida* agent of VVC in the current study was *C. krusei* (3.1%); the current results are similar to a study conducted by Mahmoudi Rad et al. (20), which reported the rate of *C. krusei* (4%). *Candida kefyr* is a rare and unusual cause of VVC as previously reported by Hedayati et al. (8.2%) (15), Rezaei-Matekolaei et al. (2.9%) (19), and Fornari et al. (2.5%) (26). However, *C. kefyr* was isolated from only one patient in the current study; the rate of *C. kefyr* isolation in the present study was 0.65%, which is lower than previous studies mentioned above. The results of this study showed that 5.63% of participants were infected with more than one species of *Candida*. This finding is in agreement with Mahmoudi Rad et al.'s, which reported the prevalence of mix infection as 10% (20).

5.1. Conclusions

Vulvovaginal candidiasis is more prevalent among females in Yasuj and the predominant agent is *C. albicans*. According to the point that excessive use of antifungal

drugs without prescription for treatment of vaginal infection can lead to induction of *Candida* resistance, correct identification of *Candida* species could play an important role in treatment of VVC.

Acknowledgments

This work was financially supported by Yasuj University of Medical Sciences (grant number 1834), Yasuj, Iran. The authors thank Professor H. Mirhendi for the molecular methods.

References

- Monroy-Perez E, Paniagua-Contreras GL, Rodriguez-Purata P, Vaca-Paniagua F, Vazquez-Villasenor M, Diaz-Velasquez C, et al. High Virulence and Antifungal Resistance in Clinical Strains of *Candida albicans*. *Can J Infect Dis Med Microbiol*. 2016;2016:5930489. doi: 10.1155/2016/5930489. [PubMed: 28058052]. [PubMed Central: PMC5183749].
- Sobel JD. Genital Candidiasis. *Sexually Transmitted Infections and Sexually Transmitted Diseases*. Springer; 2011. p. 613-24. doi:10.1007/978-3-642-14663-3_46.
- Lopes PHS, Pacini VL, Norberg AN. Genital infection by *Gardnerella vaginalis* and *Candida* spp. Among women in Nova Iguaçu city, Rio de Janeiro Province, Brazil. *Open Access Libr J*. 2017;4(3):1-7. doi:10.4236/oalib.1103366.
- Apalata T, Longo-Mbenza B, Sturm A, Carr W, Moodley P. Factors Associated with Symptomatic Vulvovaginal Candidiasis: A Study among Women Attending a Primary Healthcare Clinic in Kwazulu-Natal, South Africa. *Ann Med Health Sci Res*. 2014;4(3):410-6. doi:10.4103/2141-9248.133470. [PubMed: 24971218]. [PubMed Central: PMC4071743].
- Carlson P, Richardson M, Paavonen J. Evaluation of the Oricult-N dipslide for laboratory diagnosis of vaginal candidiasis. *J Clin Microbiol*. 2000;38(3):1063-5. [PubMed: 10698997]. [PubMed Central: PMC86339].
- Trama JP, Adelson ME, Raphaelli I, Stemmer SM, Mordechai E. Detection of *Candida* species in vaginal samples in a clinical laboratory setting. *Infect Dis Obstet Gynecol*. 2005;13(2):63-7. doi:10.1080/10647440400025629. [PubMed: 16011995]. [PubMed Central: PMC1784561].
- Lakshmi PM. Isolation and speciation of *Candida* from vaginitis cases attending gynaecology OPD in a tertiary care hospital A.P. India. *Int J Curr Microbiol App Sci*. 2016;5(10):229-32. doi: 10.20546/ijc-mas.2016.510.024.
- Boatto HF, Cavalcanti SD, Del Negro GM, Girao MJ, Francisco EC, Ishida K, et al. *Candida duobushaemulonii*: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil. *Mem Inst Oswaldo Cruz*. 2016;111(6):407-10. doi:10.1590/0074-02760160166. [PubMed: 27304096]. [PubMed Central: PMC4909041].
- Roshan R, Sabokbar A, Badali H. Identification of *Candida* species isolated from vulvovaginal candidiasis using PCR-RFLP. *Int J Mol Clin Microbiol*. 2014;4(2):406-10.
- Criseo G, Scordino F, Romeo O. Current methods for identifying clinically important cryptic *Candida* species. *J Microbiol Methods*. 2015;111:50-6. doi:10.1016/j.mimet.2015.02.004. [PubMed: 25659326].
- Mirhendi H, Makimura K, Khoramzadeh M, Yamaguchi H. A one-enzyme PCR-RFLP assay for identification of six medically important *Candida* species. *Nihon Ishinkin Gakkai Zasshi*. 2006;47(3):225-9. doi:10.3314/jjimm.47.225. [PubMed: 16940958].
- Liguori G, Lucariello A, Colella G, De Luca A, Marinelli P. Rapid identification of *Candida* species in oral rinse solutions by PCR. *J Clin Pathol*. 2007;60(9):1035-9. doi: 10.1136/jcp.2006.040782. [PubMed: 17761740]. [PubMed Central: PMC1972426].
- Luo G, Mitchell TG. Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR. *J Clin Microbiol*. 2002;40(8):2860-5. doi: 10.1128/JCM.40.8.2860-2865.2002. [PubMed: 12149343]. [PubMed Central: PMC120665].
- Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, Ghahri M, Shidfar MR, Jalalizand N, et al. Molecular identification and distribution profile of *Candida* species isolated from Iranian patients. *Med Mycol*. 2013;51(6):657-63. doi:10.3109/13693786.2013.770603. [PubMed: 23470036].
- Hedayati MT, Taheri Z, Galinimoghdam T, Aghili SR, Yazdani Cherati J, Mosayebi E. Isolation of different species of *Candida* in patients with vulvovaginal candidiasis from Sari, Iran. *Jundishapur J Microbiol*. 2015;8(4). e15992. doi: 10.5812/jjm.8(4)2015.15992. [PubMed: 26034533]. [PubMed Central: PMC4449843].
- Roudbary M, Roudbarmohammadi S, Bakhshi B, Farhadi Z, Nikoomeh F. Identification of *Candida* species isolated from Iranian women with vaginal candidiasis by PCR-RFLP method. *Eur J Exp Biol*. 2013;3(6):365-9.
- Mohamadi J, Havasian MR, Panahi J, Pakzad I. Antifungal drug resistance pattern of *Candida* spp. isolated from vaginitis in Ilam-Iran during 2013-2014. *Bioinformation*. 2015;11(4):203-6. doi:10.6026/97320630011203. [PubMed: 26124561]. [PubMed Central: PMC4479047].
- Rasti S, Asadi MA, Taghriri A, Behrashi M, Mousavie G. Vaginal candidiasis complications on pregnant women. *Jundishapur J Microbiol*. 2014;7(2). e10078. doi: 10.5812/jjm.10078. [PubMed: 25147665]. [PubMed Central: PMC4138689].
- Rezaei-Matehkolaei A, Shafiei S, Zarei-Mahmoudabadi A. Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of *Candida* species. *Iran J Microbiol*. 2016;8(6):410-7. [PubMed: 28491253]. [PubMed Central: PMC5420397].
- Mahmoudi Rad M, Zafarghandi A, Amel Zabihi M, Tavallaee M, Mirdamadi Y. Identification of *Candida* species associated with vulvovaginal candidiasis by multiplex PCR. *Infect Dis Obstet Gynecol*. 2012;2012:872169. doi:10.1155/2012/872169. [PubMed: 22791958]. [PubMed Central: PMC3389677].
- Fan SR, Liu XP, Li JW. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of *Candida* species isolates among patients in southern China from 2003 to 2006. *J Obstet Gynaecol Res*. 2008;34(4):561-6. doi: 10.1111/j.1447-0756.2008.00817.x. [PubMed: 18937710].
- Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of *Candida* species causing vulvovaginitis and epidemiology of recurrent cases. *J Clin Microbiol*. 2005;43(5):2155-62. doi:10.1128/JCM.43.5.2155-2162.2005. [PubMed: 15872235]. [PubMed Central: PMC1153777].
- Mintz JD, Martens MG. Prevalence of non-*albicans* *Candida* infections in women with recurrent vulvovaginal symptomatology. *Adv Infect Dis*. 2013;3(4):238-42. doi:10.4236/aid.2013.34035.
- Budhani D, Mehta S, Rudra S, Kumar A. Isolation, Identification and anti-fungal susceptibility of *Candida* species from clinically suspected cases of vulvovaginitis in a tertiary care hospital in rural area - a cross-sectional study. *India J Microbiol Res*. 2016;3(2):122-5. doi:10.5958/2394-5478.2016.00029.7.
- Abu-Elteen KH. Increased incidence of vulvovaginal candidiasis caused by *Candida glabrata* in Jordan. *Jpn J Infect Dis*. 2001;54(3):103-7. [PubMed: 11544399].
- Fornari G, Vicente VA, Gomes RR, Muro MD, Pinheiro RL, Ferrari C, et al. Susceptibility and molecular characterization of *Candida* species from patients with vulvovaginitis. *Braz J Microbiol*. 2016;47(2):373-80. doi:10.1016/j.bjm.2016.01.005. [PubMed: 26991298]. [PubMed Central: PMC4874609].